Weekly paclitaxel in the adjuvant treatment of breast cancer.
about
Adjuvant systemic therapy in older women with breast cancerMetronomic Chemotherapy for Metastatic Breast Cancer – a Systematic Review of the LiteratureAdjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk PatientsA Review of Systemic Treatment in Metastatic Triple-Negative Breast CancerProgress in adjuvant chemotherapy for breast cancer: an overviewCurrent approaches in treatment of triple-negative breast cancerMaternal and fetal outcomes of taxane chemotherapy in breast and ovarian cancer during pregnancy: case series and review of the literatureAdjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineOvarian cancer standard of care: are there real alternatives?Chemotherapy-induced peripheral neurotoxicity: a critical analysisAssessment of paclitaxel induced sensory polyneuropathy with "Catwalk" automated gait analysis in miceSystemic treatment strategies for triple-negative breast cancer.Triple-negative breast cancer: is there a treatment on the horizon?Long term side effects of adjuvant chemotherapy in patients with early breast cancerPertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancerNatural products and complementary therapies for chemotherapy-induced peripheral neuropathy: A systematic reviewAdjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patients[Good Prognosis! Breast Cancer Update 2016].AGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011.Pregnancy-associated breast cancer: optimal treatment options.A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial.Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer.Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy.A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer.Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG).Survival data of patients with anthracycline- or taxane-pretreated or resistant metastatic breast cancer.Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancerCritically short telomeres and toxicity of chemotherapy in early breast cancerFive-year survival of metastatic pancreatic carcinoma: a study of courage and hopeOral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.Presentation and management of docetaxel-related adverse effects in patients with breast cancerRecurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life.Epiphora in lung cancer patients receiving docetaxel: a case series.Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer.Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.Model-based meta-analysis for quantifying Paclitaxel dose response in cancer patients.Monitoring Apoptosis of Breast Cancer Xenograft After Paclitaxel Treatment With 99mTc-Labeled Duramycin SPECT/CT.Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trialPathological features of triple-negative breast cancers that showed progressive disease during neoadjuvant chemotherapy
P2860
Q26741523-82055DF0-0236-47E4-8B46-97D7B5822E3BQ26745462-20B03B5D-FF06-4CD6-84D6-AE9F9054C306Q26751253-B069D76D-716C-4250-87D4-09E5119C6376Q26752846-DF192AF4-1290-4096-877E-27A458B0A530Q26798078-1A3590AA-78F4-4A83-9078-DCC5E08C8E79Q26801549-4841E4C7-5D80-4BAB-B7EA-1E47E4F07A8BQ26827698-22A7DE33-8A35-4867-AD1A-0BBE050609BAQ26853619-081A0DB9-AE0E-467F-BEEF-86BAEC4CCD6BQ26862249-DDB3527E-5244-485D-88A5-54F34669FF18Q27010318-4067A7FD-C0DB-4AC1-930E-7124CB237A4EQ27304576-10A36A10-DFF7-48D6-9AB5-1B4E7078E414Q27691414-5650A5F7-E95B-434E-910C-4B1E57CFB4AFQ28077243-A1D1406A-4D85-4237-9564-427DFECE55F1Q28083233-B2FDAACB-12E2-4787-AD66-EF42EEA6DB82Q28246333-00F9D7A8-8C65-4DA6-9D71-6FC300233830Q28270819-1A080A8B-FB2E-451D-A2BC-9305D29EC74AQ28477739-5240A811-F9B0-40E7-845E-D26A5CA08F03Q30249775-ADDD9916-78EA-4E7C-B8F4-266F4E97C6FAQ30318240-8107B5B1-DBC0-4F14-A232-25E5779C3788Q30426275-DB6C7490-9088-45F0-A3F6-1CDD8320E337Q33387547-384BE5A2-69B9-4C6D-BD17-65AE0DD78E2EQ33388534-89C2A79B-94E9-48BF-962E-93FBDD1F95BFQ33395356-25AB49D9-3FFF-48B1-883A-F1C2DD301DB6Q33399824-F9DE0480-B902-41AC-B95C-BAF1A8C33DD8Q33407805-62AB1FB7-9213-4F55-96C5-3F1E7C505368Q33418714-CE833FD6-505B-4359-A2D8-31CCB2F28F1FQ33516882-5D8CBF6B-5D3A-4766-BEEB-EB57D19303B7Q33561953-EAF29C13-57FF-457D-936D-0627B20D0E54Q33591567-89ED19E7-FD9D-4207-8548-F12CF06C5619Q33591948-7B2CA5D2-2C13-49B3-931A-F85DBB1ACC5FQ33633424-7C8C7462-ADA3-41D1-AAE1-EFAE3E7F5649Q33698286-3A957712-2603-4FB7-9F87-CAEB71308ED5Q33703527-95A1AE9E-629C-43E3-8996-C1D5ABC39616Q33713282-AE94C8C0-3012-43E6-8B32-10AE12F8821CQ33718820-4DABA92F-2919-4141-B27C-D6CFE6517D9BQ33738990-CF8D7388-BE7A-4B44-B698-388E4C85FA8AQ33749066-6FC0F983-4EE1-4C19-B054-2CE1DAF5DBD2Q33793574-05E7A0C4-84DC-46A0-BC4B-23C3016E03C3Q33821528-799810E5-AF60-4A8E-AB58-D30A43B577F0Q33873330-B53E94D7-4672-4A61-947C-717DF6B3CA93
P2860
Weekly paclitaxel in the adjuvant treatment of breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Weekly paclitaxel in the adjuvant treatment of breast cancer.
@en
Weekly paclitaxel in the adjuvant treatment of breast cancer.
@nl
type
label
Weekly paclitaxel in the adjuvant treatment of breast cancer.
@en
Weekly paclitaxel in the adjuvant treatment of breast cancer.
@nl
prefLabel
Weekly paclitaxel in the adjuvant treatment of breast cancer.
@en
Weekly paclitaxel in the adjuvant treatment of breast cancer.
@nl
P2093
P2860
P356
P1476
Weekly paclitaxel in the adjuvant treatment of breast cancer
@en
P2093
Edith A Perez
George W Sledge
Joseph A Sparano
Molin Wang
Nancy E Davidson
Silvana Martino
Tom Saphner
Vicky Jones
William C Wood
P2860
P304
P356
10.1056/NEJMOA0707056
P407
P577
2008-04-01T00:00:00Z